A previously healthy 16-year-old boy comes to the physician because of a pruritic rash on the chest that has become progressively larger over the past 10 days. It is not painful. He is sexually active with two female partners and uses condoms inconsistently. He works part-time as a lifeguard. He has no family history of serious illness. He does not smoke. He drinks 5–6 beers on weekends. His temperature is 36.7°C (98°F), pulse is 66/min, and blood pressure is 110/70 mm Hg. A photograph of the rash is shown below. Which of the following is the most appropriate next step in management?
Q2
A 35-year-old African American male is admitted to the hospital following a recent diagnosis of systemic histoplasmosis and subsequently treated with an intravenous anti-fungal agent. During the course of his hospital stay, he complains of headaches. Work-up reveals hypotension, anemia, and elevated BUN and creatinine. His medication is known to cause these side-effects through its binding of cell membrane ergosterol. With which anti-fungal is he most likely being treated?
Q3
A 28-year-old woman with HIV comes to the physician because of an 8-day history of severe pain while swallowing. She has been hospitalized several times with opportunistic infections and has poor adherence to her antiretroviral drug regimen. Endoscopy shows extensive, white, plaque-like lesions in the proximal esophagus. Culture of a biopsy specimen grows Candida albicans. Treatment with intravenous anidulafungin is initiated. Which of the following is the primary mechanism of action of this drug?
Q4
A 12-year-old girl is brought to the physician for a follow-up examination. Two months ago, she was diagnosed with asthma and treatment was begun with an albuterol inhaler as needed. Since then, she has had episodic chest tightness and cough 2–3 times per week. The cough is intermittent and nonproductive; it is worse at night. She has been otherwise healthy and takes no other medications. Her vital signs are within normal limits. Pulmonary examination shows mild expiratory wheezing of all lung fields. Spirometry shows an FEV1:FVC ratio of 81% and an FEV1 of 80% of predicted; FEV1 rises to 93% of predicted after administration of a short-acting bronchodilator. Treatment with low-dose inhaled beclomethasone is begun. The patient is at greatest risk for which of the following adverse effects?
Q5
A 45-year-old man presents to the emergency department with difficulties swallowing food. He states that he experiences pain when he attempts to swallow his medications or when he drinks water. He reveals that he was diagnosed with HIV infection five years ago. He asserts that he has been taking his antiretroviral regimen, including emtricitabine, rilpivirine, and tenofovir. His temperature is 98°F (37°C), blood pressure is 100/60 mmHg, pulse is 90/min, respirations are 22/min, and oxygen saturation is 99% on room air. His physical exam is notable for a clear oropharynx, no lymphadenopathy, and a normal cardiac and pulmonary exam. No rashes are noted throughout his body. His laboratory results are displayed below:
Hemoglobin: 12 g/dL
Hematocrit: 37 %
Leukocyte count: 8,000/mm^3 with normal differential
Platelet count: 160,000/mm^3
Serum:
Na+: 138 mEq/L
Cl-: 108 mEq/L
K+: 3.5 mEq/L
HCO3-: 26 mEq/L
BUN: 35 mg/dL
Glucose: 108 mg/dL
Creatinine: 1.1 mg/dL
CD4+ count: 90/mm^3
HIV viral load: 59,000 copies/mL
What is the best next step in management?
Q6
A 9-year-old African-American boy is brought to the physician by his mother because of an itchy rash on the right side of his scalp and progressive loss of hair for 1 month. He has no history of serious illness. His younger sibling was treated for pediculosis capitis 3 months ago. The boy attends elementary school, but has not been going for the last week because he was too embarrassed by the rash. He appears anxious. A photograph of his scalp is shown. Occipital lymphadenopathy is present. The remainder of the examination shows no abnormalities. Which of the following is the most appropriate next step in management?
Q7
A 45-year-old man comes to the physician because of a 3-day history of pain in his mouth and throat and difficulty swallowing. He has a history of COPD, for which he takes theophylline and inhaled budesonide-formoterol. Physical examination shows white patches on the tongue and buccal mucosa that can be scraped off easily. Appropriate pharmacotherapy is initiated. One week later, he returns because of nausea, palpitations, and anxiety. His pulse is 110/min and regular. Physical examination shows a tremor in both hands. Which of the following drugs was most likely prescribed?
Q8
A 74-year-old man is admitted to the medical ward after he developed a fungal infection. He has aplastic anemia. The most recent absolute neutrophil count was 450/µL. An anti-fungal agent is administered that inhibits the fungal enzyme, (1→3)-β-D-glucan synthase, and thereby disrupts the integrity of the fungal cell wall. He responds well to the treatment. Although amphotericin B is more efficacious for his condition, it was not used because of the side effect profile. What was the most likely infection?
Q9
A 57-year-old woman with non-small cell lung cancer comes to the physician 4 weeks after her tumor was resected. She takes no medications. The physician starts her on a treatment regimen that includes vinblastine. This treatment puts the patient at highest risk for which of the following?
Q10
A 46-year-old man with HIV infection comes to the physician because of a 1-week history of severe retrosternal pain while swallowing. He has not been compliant with his antiretroviral drug regimen. His CD4+ T-lymphocyte count is 98/mm3 (N ≥ 500). Endoscopy shows white plaques in the esophagus. The most appropriate immediate treatment is a drug that inhibits which of the following enzymes?
Antifungals US Medical PG Practice Questions and MCQs
Question 1: A previously healthy 16-year-old boy comes to the physician because of a pruritic rash on the chest that has become progressively larger over the past 10 days. It is not painful. He is sexually active with two female partners and uses condoms inconsistently. He works part-time as a lifeguard. He has no family history of serious illness. He does not smoke. He drinks 5–6 beers on weekends. His temperature is 36.7°C (98°F), pulse is 66/min, and blood pressure is 110/70 mm Hg. A photograph of the rash is shown below. Which of the following is the most appropriate next step in management?
A. Topical miconazole (Correct Answer)
B. Phototherapy
C. Reassurance
D. Topical erythromycin
E. Topical hydrocortisone
Explanation: **Topical miconazole**
- The rash described, especially in a lifeguard who is frequently exposed to moisture, suggests **tinea corporis** (ringworm), a **dermatophyte fungal infection**.
- **Topical imidazole antifungals** like miconazole are the first-line treatment for localized tinea infections.
*Phototherapy*
- **Phototherapy** (e.g., UVB or PUVA) is used for chronic widespread dermatoses like **psoriasis** or severe **atopic dermatitis**, not typically for localized fungal infections.
- This rash is likely **infectious** and requires an antifungal agent for resolution.
*Reassurance*
- The rash is described as **progressively larger** and **pruritic**, indicating an active and symptomatic process that requires intervention, not just reassurance.
- Delaying treatment could lead to further spread or secondary bacterial infection.
*Topical erythromycin*
- **Topical erythromycin** is an **antibiotic** used to treat bacterial skin infections, such as **acne vulgaris** or impetigo.
- It would be ineffective against a fungal infection like tinea corporis.
*Topical hydrocortisone*
- **Topical hydrocortisone** is a **corticosteroid** that reduces inflammation and itching.
- While it might temporarily alleviate symptoms, it can actually worsen fungal infections by suppressing the local immune response, leading to **tinea incognito**.
Question 2: A 35-year-old African American male is admitted to the hospital following a recent diagnosis of systemic histoplasmosis and subsequently treated with an intravenous anti-fungal agent. During the course of his hospital stay, he complains of headaches. Work-up reveals hypotension, anemia, and elevated BUN and creatinine. His medication is known to cause these side-effects through its binding of cell membrane ergosterol. With which anti-fungal is he most likely being treated?
A. Griseofulvin
B. Amphotericin B (Correct Answer)
C. Flucytosine
D. Fluconazole
E. Terbinafine
Explanation: ***Amphotericin B***
- **Amphotericin B** is known for its significant side effects, including **nephrotoxicity** (leading to elevated BUN and creatinine, and potentially anemia due to reduced erythropoietin production) and **infusion-related reactions** like headache and hypotension.
- It works by binding to **ergosterol** in fungal cell membranes, forming pores that lead to cell death, but it can also bind to cholesterol in mammalian cell membranes contributing to its toxicity.
*Griseofulvin*
- **Griseofulvin** primarily acts by binding to **keratin** and interfering with fungal **mitosis**; it does not bind to ergosterol.
- Its main side effects include **GI upset**, headache, and photosensitivity, but not prominent nephrotoxicity or hypotension in the manner described.
*Flucytosine*
- **Flucytosine** is an antimetabolite that is converted to **5-fluorouracil** within fungal cells, interfering with RNA and DNA synthesis. It does not bind to ergosterol.
- Its major adverse effects include **bone marrow suppression** (leukopenia, thrombocytopenia) and liver enzyme elevation, not the constellation of symptoms (hypotension, renal failure) described.
*Fluconazole*
- **Fluconazole** is an azole antifungal that inhibits **ergosterol synthesis** by blocking fungal cytochrome P450 enzymes. It does not directly bind to ergosterol.
- While it can cause some GI upset and liver enzyme elevation, it is generally well-tolerated and less associated with acute nephrotoxicity or hypotension compared to Amphotericin B.
*Terbinafine*
- **Terbinafine** inhibits **squalene epoxidase**, an enzyme involved in ergosterol synthesis, rather than binding directly to ergosterol itself.
- Its main side effects include **GI disturbances**, headache, and liver enzyme abnormalities, but typically not the severe nephrotoxicity and hypotension associated with Amphotericin B.
Question 3: A 28-year-old woman with HIV comes to the physician because of an 8-day history of severe pain while swallowing. She has been hospitalized several times with opportunistic infections and has poor adherence to her antiretroviral drug regimen. Endoscopy shows extensive, white, plaque-like lesions in the proximal esophagus. Culture of a biopsy specimen grows Candida albicans. Treatment with intravenous anidulafungin is initiated. Which of the following is the primary mechanism of action of this drug?
A. Binding to tubulin
B. Inhibition of squalene epoxidase
C. Decreased DNA synthesis
D. Binding to ergosterol
E. Decreased glucan synthesis (Correct Answer)
Explanation: ***Decreased glucan synthesis***
- **Anidulafungin** is an **echinocandin** antifungal drug that inhibits the synthesis of **β-(1,3)-D-glucan**, a crucial component of the fungal cell wall.
- By disrupting the fungal cell wall, **anidulafungin** causes **osmotic instability** and ultimately leads to cell lysis and death, making it effective against *Candida* infections.
*Binding to tubulin*
- This is the mechanism of action of **griseofulvin**, an antifungal agent primarily used for dermatophyte infections.
- **Griseofulvin** interferes with **microtubule formation**, thus inhibiting fungal mitosis.
*Inhibition of squalene epoxidase*
- This is the mechanism of action of **terbinafine**, an antifungal drug commonly used for dermatophyte infections like onychomycosis.
- **Terbinafine** blocks the synthesis of **ergosterol**, an essential component of the fungal cell membrane, by inhibiting **squalene epoxidase**.
*Decreased DNA synthesis*
- This mechanism is associated with **flucytosine**, an antifungal agent that is converted to 5-fluorouracil inside fungal cells.
- **Flucytosine** then inhibits fungal **DNA and RNA synthesis** and is often used in combination with amphotericin B for severe systemic candidiasis or cryptococcosis.
*Binding to ergosterol*
- This is the mechanism of action of **polyene antifungals** like **amphotericin B** and **nystatin**.
- These drugs bind to **ergosterol** in the fungal cell membrane, forming pores that lead to leakage of intracellular contents and cell death.
Question 4: A 12-year-old girl is brought to the physician for a follow-up examination. Two months ago, she was diagnosed with asthma and treatment was begun with an albuterol inhaler as needed. Since then, she has had episodic chest tightness and cough 2–3 times per week. The cough is intermittent and nonproductive; it is worse at night. She has been otherwise healthy and takes no other medications. Her vital signs are within normal limits. Pulmonary examination shows mild expiratory wheezing of all lung fields. Spirometry shows an FEV1:FVC ratio of 81% and an FEV1 of 80% of predicted; FEV1 rises to 93% of predicted after administration of a short-acting bronchodilator. Treatment with low-dose inhaled beclomethasone is begun. The patient is at greatest risk for which of the following adverse effects?
A. Hypoglycemia
B. Easy bruisability
C. Oropharyngeal candidiasis (Correct Answer)
D. Bradycardia
E. High-pitched voice
Explanation: ***Oropharyngeal candidiasis***
- **Inhaled corticosteroids** like beclomethasone can suppress the local immune response in the oral cavity and pharynx, leading to opportunistic fungal infections.
- This condition, commonly known as **thrush**, presents as white patches on the tongue and oral mucosa, which can be mitigated by rinsing the mouth after inhaler use.
*Hypoglycemia*
- **Inhaled corticosteroids** typically have minimal systemic absorption at low doses and are not associated with hypoglycemia.
- **Hypoglycemia** is more commonly associated with diabetes treatment or conditions affecting glucose regulation.
*Easy bruisability*
- While **systemic corticosteroids** can cause skin thinning and easy bruising with long-term use, **inhaled corticosteroids** at low doses have very limited systemic effects.
- The risk of easy bruisability is extremely low with the prescribed treatment in this patient.
*Bradycardia*
- **Beta-agonists** (like albuterol) can cause tachycardia, but inhaled corticosteroids themselves do not significantly affect heart rate.
- **Bradycardia** is not a characteristic adverse effect of beclomethasone; it is typically associated with certain cardiac conditions or medications like beta-blockers.
*High-pitched voice*
- **Inhaled corticosteroids** can sometimes lead to hoarseness or dysphonia due to local irritation or candidiasis of the vocal cords, but not specifically to a high-pitched voice.
- A high-pitched voice is not a recognized adverse effect; rather, a change in voice quality such as hoarseness is more typical.
Question 5: A 45-year-old man presents to the emergency department with difficulties swallowing food. He states that he experiences pain when he attempts to swallow his medications or when he drinks water. He reveals that he was diagnosed with HIV infection five years ago. He asserts that he has been taking his antiretroviral regimen, including emtricitabine, rilpivirine, and tenofovir. His temperature is 98°F (37°C), blood pressure is 100/60 mmHg, pulse is 90/min, respirations are 22/min, and oxygen saturation is 99% on room air. His physical exam is notable for a clear oropharynx, no lymphadenopathy, and a normal cardiac and pulmonary exam. No rashes are noted throughout his body. His laboratory results are displayed below:
Hemoglobin: 12 g/dL
Hematocrit: 37 %
Leukocyte count: 8,000/mm^3 with normal differential
Platelet count: 160,000/mm^3
Serum:
Na+: 138 mEq/L
Cl-: 108 mEq/L
K+: 3.5 mEq/L
HCO3-: 26 mEq/L
BUN: 35 mg/dL
Glucose: 108 mg/dL
Creatinine: 1.1 mg/dL
CD4+ count: 90/mm^3
HIV viral load: 59,000 copies/mL
What is the best next step in management?
A. Fluconazole (Correct Answer)
B. Nystatin
C. Oral swab and microscopy
D. Methylprednisolone
E. Esophageal endoscopy and biopsy
Explanation: ***Fluconazole***
- The patient's **odynophagia**, low **CD4+ count**, and high **HIV viral load** are highly suggestive of **esophageal candidiasis**.
- **Fluconazole** is the initial empiric treatment of choice for suspected esophageal candidiasis in HIV-positive patients, given its high efficacy and good tolerability.
*Nystatin*
- **Nystatin** is typically used for **oral candidiasis (thrush)**, which presents with white plaques in the mouth.
- The patient has a **clear oropharynx** and **odynophagia**, indicating esophageal involvement, for which nystatin is less effective.
*Oral swab and microscopy*
- While an **oral swab** can confirm oral candidiasis, it is not sufficient for diagnosing **esophageal candidiasis**.
- Given the patient's symptoms of odynophagia and high clinical suspicion in an immunocompromised patient, empiric treatment is preferred over initial diagnostic testing for uncomplicated esophageal candidiasis.
*Methylprednisolone*
- **Methylprednisolone** is a corticosteroid used to reduce inflammation and is not indicated for the treatment of **candidal infections**.
- Using corticosteroids in an immunocompromised patient with an active opportunistic infection could worsen his condition.
*Esophageal endoscopy and biopsy*
- **Esophageal endoscopy and biopsy** are typically reserved for patients who **fail empiric antifungal therapy** or present with **atypical symptoms** not consistent with candidiasis.
- Given the clear clinical picture, initial empiric treatment with fluconazole is the standard first step.
Question 6: A 9-year-old African-American boy is brought to the physician by his mother because of an itchy rash on the right side of his scalp and progressive loss of hair for 1 month. He has no history of serious illness. His younger sibling was treated for pediculosis capitis 3 months ago. The boy attends elementary school, but has not been going for the last week because he was too embarrassed by the rash. He appears anxious. A photograph of his scalp is shown. Occipital lymphadenopathy is present. The remainder of the examination shows no abnormalities. Which of the following is the most appropriate next step in management?
A. Topical mupirocin
B. Topical permethrin
C. Oral griseofulvin (Correct Answer)
D. Calcipotriene
E. Shampoo containing zinc pyrithione
Explanation: ***Oral griseofulvin***
- This patient presents with symptoms highly suggestive of **tinea capitis (ringworm of the scalp)**, which is characterized by an **itchy rash**, **hair loss**, and **occipital lymphadenopathy**. Oral antifungal treatment, such as **griseofulvin**, is the **most appropriate initial management** for tinea capitis because topical agents alone are generally ineffective due to the infection's deep follicular location.
- **Griseofulvin** acts by inhibiting fungal cell division and is deposited in keratin precursor cells, making the newly grown hair resistant to fungal invasion. It is highly effective against dermatophytes causing tinea capitis.
*Topical mupirocin*
- **Mupirocin** is an **antibiotic** used to treat **bacterial skin infections**, such as impetigo.
- It would not be effective against **tinea capitis**, which is a fungal infection, and thus is an inappropriate treatment.
*Topical permethrin*
- **Permethrin** is a **topical insecticide** primarily used to treat **pediculosis (lice infestations)** and scabies.
- While the patient's sibling had pediculosis, the patient's symptoms (itchy rash, hair loss, lymphadenopathy) are more consistent with **tinea capitis**, a fungal infection, making permethrin ineffective.
*Calcipotriene*
- **Calcipotriene** is a **vitamin D analog** used topically to treat **psoriasis** by slowing down the excessive growth of skin cells.
- It has no antifungal properties and would not be effective in treating **tinea capitis**.
*Shampoo containing zinc pyrithione*
- **Zinc pyrithione** is an antifungal and antibacterial agent commonly found in shampoos for treating conditions like **seborrheic dermatitis (dandruff)** and mild forms of tinea versicolor.
- While it has some antifungal properties, it is generally **insufficient as a sole treatment** for **tinea capitis**, which requires systemic antifungal therapy due to the involvement of hair follicles.
Question 7: A 45-year-old man comes to the physician because of a 3-day history of pain in his mouth and throat and difficulty swallowing. He has a history of COPD, for which he takes theophylline and inhaled budesonide-formoterol. Physical examination shows white patches on the tongue and buccal mucosa that can be scraped off easily. Appropriate pharmacotherapy is initiated. One week later, he returns because of nausea, palpitations, and anxiety. His pulse is 110/min and regular. Physical examination shows a tremor in both hands. Which of the following drugs was most likely prescribed?
A. Amphotericin B
B. Griseofulvin
C. Terbinafine
D. Fluconazole (Correct Answer)
E. Nystatin
Explanation: ***Fluconazole***
- Fluconazole is a potent **CYP450 inhibitor**, specifically **CYP2C9 and CYP3A4**, which can significantly increase the levels of drugs metabolized by these enzymes, such as **theophylline**.
- The patient's symptoms of nausea, palpitations, anxiety, tremor, and tachycardia are consistent with **theophylline toxicity**, which would be exacerbated by co-administration with fluconazole.
*Amphotericin B*
- Amphotericin B is a powerful antifungal, but its primary side effects include **nephrotoxicity**, **infusion-related reactions** (fever, chills, rigors), and **electrolyte disturbances**, not theophylline toxicity.
- It is typically reserved for **severe systemic fungal infections** and is not a first-line treatment for uncomplicated **oral candidiasis**.
*Griseofulvin*
- Griseofulvin is used to treat **dermatophyte infections** (tinea infections) and is not active against *Candida*.
- Its main side effects include **gastrointestinal upset**, **headache**, and **photosensitivity**, and it does not significantly interact with theophylline.
*Terbinafine*
- Terbinafine is an allylamine antifungal primarily used for **dermatophyte infections**, particularly **onychomycosis**, and is not effective for candidiasis.
- While it can cause liver enzyme elevation, it does not typically lead to theophylline toxicity or the constellation of symptoms described.
*Nystatin*
- Nystatin is a **topical or oral non-absorbable antifungal** used for superficial candidal infections, including oral thrush.
- It is not absorbed systemically, so it has **virtually no drug interactions** or systemic side effects, and therefore would not cause theophylline toxicity.
Question 8: A 74-year-old man is admitted to the medical ward after he developed a fungal infection. He has aplastic anemia. The most recent absolute neutrophil count was 450/µL. An anti-fungal agent is administered that inhibits the fungal enzyme, (1→3)-β-D-glucan synthase, and thereby disrupts the integrity of the fungal cell wall. He responds well to the treatment. Although amphotericin B is more efficacious for his condition, it was not used because of the side effect profile. What was the most likely infection?
A. Invasive aspergillosis
B. Mucormycosis
C. Histoplasmosis
D. Paracoccidioidomycosis
E. Candidemia (Correct Answer)
Explanation: ***Candidemia***
- The patient's **neutropenia** (absolute neutrophil count of 450/µL) due to aplastic anemia is a major risk factor for invasive candidiasis, including candidemia.
- The antifungal agent's mechanism of action, targeting **(1→3)-β-D-glucan synthase**, is characteristic of **echinocandins**, which are first-line agents for candidemia, especially in critically ill or neutropenic patients, and often preferred over amphotericin B due to a better side effect profile.
*Invasive aspergillosis*
- While neutropenia is a significant risk factor for invasive aspergillosis, the primary antifungal drugs for this condition are typically **voriconazole** or **isavuconazole**, although echinocandins may be used as salvage therapy or in combination.
- The description of the drug's mechanism specifically targeting **(1→3)-β-D-glucan synthase** does not make aspergillosis the *most likely* infection, as some Aspergillus species may have less β-D-glucan in their cell walls compared to *Candida*.
*Mucormycosis*
- This aggressive fungal infection is often seen in immunocompromised patients, particularly those with **diabetes** or profound neutropenia, but the primary treatment is usually **amphotericin B**.
- Mucorales fungi typically **lack ergosterol** and their cell walls do not contain **(1→3)-β-D-glucan**, making echinocandins ineffective.
*Histoplasmosis*
- This is a dimorphic fungal infection endemic to certain geographic regions, primarily affecting the lungs and disseminating in immunocompromised individuals.
- The drug of choice for severe or disseminated histoplasmosis is **amphotericin B**, followed by azoles; echinocandins are generally not active against *Histoplasma*.
*Paracoccidioidomycosis*
- This is a chronic systemic mycosis found in Latin America, primarily affecting the lungs, skin, and lymph nodes.
- Treatment for severe forms typically involves **amphotericin B**, followed by sulfonamides or azoles for maintenance; echinocandins are not effective against *Paracoccidioides*.
Question 9: A 57-year-old woman with non-small cell lung cancer comes to the physician 4 weeks after her tumor was resected. She takes no medications. The physician starts her on a treatment regimen that includes vinblastine. This treatment puts the patient at highest risk for which of the following?
A. Pulmonary embolism
B. Invasive fungal infection (Correct Answer)
C. Progressive multifocal leukoencephalopathy
D. Pulmonary fibrosis
E. Heart failure
Explanation: ***Invasive fungal infection***
- Vinblastine is an **antimitotic chemotherapy agent** that, like other chemotherapeutic agents, can cause **myelosuppression**.
- **Myelosuppression** (particularly **neutropenia**) severely compromises the immune system, making patients highly susceptible to **opportunistic infections**, including invasive fungal infections.
*Pulmonary embolism*
- While cancer itself is a risk factor for **venous thromboembolism**, including pulmonary embolism, vinblastine itself **does not directly increase the risk** more than other chemotherapy agents.
- The highest risk with vinblastine specifically relates to its impact on bone marrow.
*Progressive multifocal leukoencephalopathy*
- This is a rare, severe opportunistic infection of the brain caused by the **JC virus**, primarily seen in patients with **severe immunosuppression**, such as those with HIV/AIDS or on chronic immunosuppressive therapy (e.g., natalizumab).
- While chemotherapy can cause immunosuppression, PML is not the most common or highest specific risk directly associated with vinblastine or its immediate, acute side effects compared to myelosuppression and opportunistic infections.
*Pulmonary fibrosis*
- **Pulmonary fibrosis** is a known side effect of certain chemotherapeutic agents like **bleomycin** and **busulfan**, but it is **not a primary or common adverse effect of vinblastine**.
- The side effect profile of vinblastine primarily involves myelosuppression, neurotoxicity, and gastrointestinal effects.
*Heart failure*
- **Cardiotoxicity leading to heart failure** is a significant concern with certain chemotherapy drugs, particularly **anthracyclines** (e.g., doxorubicin) and some tyrosine kinase inhibitors.
- **Vinblastine is not typically associated with cardiotoxicity or heart failure** as a primary or high-risk adverse effect.
Question 10: A 46-year-old man with HIV infection comes to the physician because of a 1-week history of severe retrosternal pain while swallowing. He has not been compliant with his antiretroviral drug regimen. His CD4+ T-lymphocyte count is 98/mm3 (N ≥ 500). Endoscopy shows white plaques in the esophagus. The most appropriate immediate treatment is a drug that inhibits which of the following enzymes?
A. DNA polymerase
B. Hydrogen-potassium ATPase
C. Cytochrome p450 enzymes (Correct Answer)
D. Phospholipase A2
E. Squalene epoxidase
Explanation: ***Cytochrome P450 enzymes***
- The patient's symptoms (retrosternal pain on swallowing, white plaques on endoscopy) and severely low **CD4+ count (98/mm³)** are highly suggestive of **esophageal candidiasis**, a common opportunistic infection in AIDS.
- **Fluconazole**, an azole antifungal, is the **first-line treatment** for esophageal candidiasis and works by inhibiting **14α-demethylase (lanosterol demethylase)**, a fungal **cytochrome P450 enzyme**.
- This inhibition prevents the conversion of lanosterol to ergosterol, disrupting **fungal cell membrane synthesis** and leading to fungal cell death.
*Squalene epoxidase*
- **Terbinafine** and **naftifine** (allylamine antifungals) inhibit squalene epoxidase in the ergosterol synthesis pathway.
- These agents are primarily used for **dermatophyte infections** (onychomycosis, tinea) and have **poor activity against Candida species**.
- They are not appropriate for treating esophageal candidiasis.
*DNA polymerase*
- Inhibitors of **DNA polymerase**, such as acyclovir or ganciclovir, are used to treat **herpesvirus infections** (HSV, CMV).
- While herpes esophagitis can occur in immunocompromised patients, it typically presents with **punched-out ulcers**, not white plaques.
*Hydrogen-potassium ATPase*
- **Proton pump inhibitors** (PPIs) target hydrogen-potassium ATPase in gastric parietal cells to reduce **acid secretion**.
- These are used to treat **GERD** or **peptic ulcers**, which do not present with white plaques on endoscopy.
- While PPIs may provide symptomatic relief, they do not treat the underlying fungal infection.
*Phospholipase A2*
- Phospholipase A2 inhibitors are used as **anti-inflammatory agents**, as PLA2 releases arachidonic acid, a precursor to inflammatory mediators.
- These drugs have no role in treating fungal infections like esophageal candidiasis.